



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Inflectra (infliximab-dyyb)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Form with fields for Patient Name, Member/Subscriber Number, Date of Birth, Group Number, Address, City, State ZIP, Primary Phone, Prescriber Name, Supervising Physician, Fax, Office Contact, NPI, Address, City, State ZIP, Specialty/facility name, Phone, and State Lic ID.

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. What diagnosis is this drug being prescribed for (select ALL that apply)?

- List of medical conditions with checkboxes: Ankylosing Spondylitis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Acute Graft-Versus-Host Disease, Adult Onset Still's Disease, Arthropathy in Inflammatory Disease, Behcet's Syndrome, Early Synovitis in Rheumatoid Arthritis, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Kawasaki Disease, Pyoderma Gangrenosum, Reiter's Disease, SAPHO Syndrome, Sarcoidosis, Takayasu's Disease, Uveitis, Uveitis in Behcet's Syndrome, Wegener's Granulomatosis, Other.

Q2. Select the regimen being requested.

- Regimen options with checkboxes: 5 mg/kg every 6 weeks, 3 mg/kg every 8 weeks, 5 mg/kg every 8 weeks.



# PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

## Inflectra (infliximab-dyyb)

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
<input type="checkbox"/> 10 mg/kg every 8 weeks <input type="checkbox"/> Other (please specify)	
Q3. Provide ICD code(s) for diagnosis.	
Q4. What is the patient's weight?	
Q5. Is this a new start for this patient? If not, please specify start date. <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q6. Does the patient have failure to brand Remicade and Renflexis? Failure is defined as a history of a trial of at least 14 weeks of preferred agents resulting in minimal clinical response to therapy and residual disease activity. <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. Does the physician attest that, in their clinical opinion, the clinical response would be expected to be superior with Inflectra, than experienced with Remicade and Renflexis? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. Does the patient have a history of intolerance or adverse event to brand Remicade and Renflexis? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Does the physician attest that, in their clinical opinion, the same intolerance or adverse event would not be expected to occur with Inflectra? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. Please select all that apply to the patient <input type="checkbox"/> Loss of a favorable response after established maintenance therapy with Remicade or Renflexis <input type="checkbox"/> Developed neutralizing antibodies to any infliximab biosimilar product that has led to an attenuation of efficacy of therapy <input type="checkbox"/> Previously stable on Remicade or Renflexis and switched to Inflectra <input type="checkbox"/> None of the above	
Q11. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement? <input type="checkbox"/> Pharmacy	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Inflectra (infliximab-dyyb)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Form with fields for Patient Name, Prescriber Name, Supervising Physician, and questions Q12, Q13, and Q14.

Prescriber Signature

Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



## PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

# Inflectra (infliximab-dyyb)

Phone: 800-728-7947

Fax back to: 866-880-4532

---

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

---

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
----------------------	--

---